31st Aug 2011 07:00
For immediate release | 30 August 2011 |
ABCAM PLC
("Abcam" or "the Company")
PDMR Dealings: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, was today notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of certain of its PDMRs in line with their commitment to participate in the SIP on a monthly basis:
Name | Partnership Shares purchased on 26 August 2011 at 336.4475 pence per share | Matching Shares awarded on 26 August 2011 at 336.4475 pence per share |
Mark Bushfield | 37 | 37 |
Philippe Cotrel | 37 | 37 |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on the release of these shares.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality research-grade antibodies and associated proteomics research products. Antibodies and related products are essential tools for life scientists enabling them to analyse components of living cells at the molecular level.
The Group sells through the internet to customers in most countries of the world, and now has an online catalogue of products sourced from over 250 of the world's leading primary manufacturers, academic laboratories and institutes, and the Group also produces its own antibodies in its own production facilities. The catalogue includes a growing range of non-antibody products such as proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and are distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research and detection tools globally.
Related Shares:
ABC.L